Anti-PD-1/CD47 Fusion Protein HX009 clinical trials
Also written HX009.
Its developmentBy Hangzhou Hanx Biopharmaceuticals and Waterstone Hanxbio Pty, step by step5 company-led studies, furthest phase 2: when each phase was reached, its deals, target and what is ahead.How each study uses Anti-PD-1/CD47 Fusion Protein HX009 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Anti-PD-1/CD47 Fusion Protein HX009 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- HX009
- 3
Studies by the year they started
4 studies that test it; most in 2019 (1)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2021 | 1 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 0
Hangzhou Hanx Biopharmaceuticals, Ltd. (3) · Waterstone Hanxbio Pty Ltd (1)
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
Studies
Open first, then newest update. How each study uses Anti-PD-1/CD47 Fusion Protein HX009 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid TumoursRecruitingPhase 1/2Hangzhou Hanx Biopharmaceuticals, Ltd.NCT06708663Written as HX009+IN10018
- Recombinant Humanized Anti-CD47 / PD-1 Bifunctional Antibody HX009 Injection in the Treatment of Advanced Solid TumorsCompletedPhase 2Hangzhou Hanx Biopharmaceuticals, Ltd.NCT04886271Written as HX009
- Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid TumorsActive, not recruitingPhase 1Hangzhou Hanx Biopharmaceuticals, Ltd.NCT05731752Written as HX009
- The Safety, Tolerability, and Initial Efficacy of HX009 in Patients With Advanced MalignanciesCompletedPhase 1Waterstone Hanxbio Pty LtdNCT04097769Written as HX009